Keytruda (pembrolizumab) | Friends of Cancer Research

You are here

Keytruda (pembrolizumab)

Sponsor: 
Merck Sharp & Dohme Corp
Indication: 
In combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for surgery or radiation
Category: 
Year: 
2018
Date: 
Aug 1st
FDA Status: 
FDA Approval
Approval Date: 
Sep 17th
Approval Year: 
2019